Weekly Recap | Gilead Sciences -4.82%, most brokers rate it buyWeekly Review·Sep 12 at 08:16 AMGILD+2.17%
Weekly Recap | Vertex Pharma -5.62%, low-volume pullback lags the S&P 500Weekly Review·Sep 12 at 07:06 AMVRTX+0.60%
Weekly Recap | Roivant Sciences +16.86%, closing in on record highsWeekly Review·Sep 12 at 06:42 AMROIV+1.04%
Weekly Recap | Revolution Medicines -2.98%, consensus target above spotWeekly Review·Sep 12 at 06:40 AMRVMD+0.52%
Weekly Recap | Regeneron Pharma -5.59%, class action deadline passesWeekly Review·Sep 12 at 06:39 AMREGN+1.92%
Weekly Recap | Moderna -1.09%, tumour vaccine milestoneWeekly Review·Sep 12 at 06:22 AMMRNA+8.55%MRNY+5.57%
Weekly Recap | Alnylam Pharma -6.55%, consensus target above spotWeekly Review·Sep 12 at 05:55 AMALNY+2.57%
Weekly Recap | Vertex Pharma +0.82%, closing in on record highsWeekly Review·Sep 5 at 08:25 AMVRTX+0.60%
Weekly Recap | Regeneron Pharma +4.22%, closing in on record highsWeekly Review·Sep 5 at 07:49 AMREGN+1.92%
Weekly Recap | Moderna +5.48%, consensus target below spotWeekly Review·Sep 5 at 07:36 AMMRNA+8.55%MRNY+5.57%
Weekly Recap | Gilead Sciences +3.65%, FDA approves new HIV tabletWeekly Review·Sep 5 at 07:02 AMGILD+2.17%
Weekly Recap | Vertex Pharma -1.16%, most brokers rate it buyWeekly Review·Aug 29 at 06:39 AMVRTX+0.60%
Weekly Recap | Regeneron Pharma -4.78%, consensus target above spotWeekly Review·Aug 29 at 06:22 AMREGN+1.92%
